The launch of the LucentAD test by Quanterix is directly related to the company's product portfolio and could potentially increase its market share in the healthcare sector. The test, which is designed to assist in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer's disease, fills a significant need in the market. Furthermore, the announcement of additional tests for Alzheimer's and other neurological disorders could further strengthen the company's position in this sector.